GATC Health Releases Scientific Article Validating Its Opioid Use Disorder Drug Candidate in Animal Studies at UCI

GATC-021 substantially reduced fentanyl intake in both male and female rats, as assessed with intravenous self-administration.

IRVINE, CA. – March, 2024 – GATC Health Corp’s scientific article, “AI Derived Therapeutic Development for the Treatment of Opioid Use Disorder,” is now available to the public. This paper documents a recent study performed at University of California, Irvine, where GATC Health’s new drug candidate was shown to be highly effective at reducing self-administration of fentanyl in addicted rats.

Publication available here.

To read the full article, follow the “Download PDF” link to the right of the title.

About GATC Health
GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which derisks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency, and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions the future of medicine now, where health is protected, disease is reversed, and every person’s unique biology is treated with precision.